Teplizumab in New-Onset Type 1 Diabetes

Teplizumab in New-Onset Type 1 Diabetes

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is no longer recruiting.

Description
This is a study that investigates whether an IV medication (teplizumab) will slow or halt the progression of type 1 diabetes in children and adolescents (ages 8 - 17 years). Eligible participants will be randomly assigned to receive either the study medication or an inactive substance called a placebo. All participants will receive two courses of IV infusions, six months apart from each other. During each treatment course, participants will come to CHOP for daily teplizumab or placebo infusions for 12 days. Study participation, including treatments and follow-up visits, lasts for 1.5 years.

Eligibility and criteria
IRB Number:
19-016332
Eligible age range:
8 years - 17 years
Clinical trial phase:
Phase III
Official title:
A Phase 3, randomized, double-blind, multinational, placebo-controlled study to evaluate efficacy and safety of teplizumab (PRV-031), a humanized, FcR non-binding, anti-CD3 monoclonal antibody, in children and adolescents with newly diagnosed Type 1 diabetes (T1D)
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.